Bendamustine hydrochloride - Generic Drug Details

What are the generic drug sources for bendamustine hydrochloride and what is the scope of patent protection?

Bendamustine hydrochloride is the generic ingredient in five branded drugs marketed by Accord Hlthcare, Apotex, Breckenridge, Dr Reddys, Eugia Pharma, Meitheal, Nang Kuang Pharm Co, Pharmobedient, Cephalon, Eagle Pharms, Baxter Hlthcare Corp, Hospira, and Azurity, and is included in sixteen NDAs. There are thirty-three patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Bendamustine hydrochloride has one hundred and fifty-seven patent family members in thirty-two countries.

There are sixteen drug master file entries for bendamustine hydrochloride. Eleven suppliers are listed for this compound. There are six tentative approvals for this compound.

Summary for bendamustine hydrochloride

International Patents:	157
US Patents:	33
Tradenames:	5
Applicants:	13
NDAs:	16
Drug Master File Entries:	16
Finished Product Suppliers / Packagers:	11
Raw Ingredient (Bulk) Api Vendors:	97
Clinical Trials:	408
Patent Applications:	5,521
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for bendamustine hydrochloride
What excipients (inactive ingredients) are in bendamustine hydrochloride?	bendamustine hydrochloride excipients list
DailyMed Link:	bendamustine hydrochloride at DailyMed

Recent Clinical Trials for bendamustine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fred Hutchinson Cancer Center	PHASE1
Guangzhou Lupeng Pharmaceutical Company LTD.	PHASE2
National Taiwan University Hospital	PHASE2

See all bendamustine hydrochloride clinical trials

Generic filers with tentative approvals for BENDAMUSTINE HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		100MG/VIAL	POWDER;IV (INFUSION)
		25MG/VIAL	POWDER;IV (INFUSION)
		100MG/VIAL	POWDER;IV (INFUSION)

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for bendamustine hydrochloride

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

Medical Subject Heading (MeSH) Categories for bendamustine hydrochloride

Antineoplastic Agents, Alkylating

Anatomical Therapeutic Chemical (ATC) Classes for bendamustine hydrochloride

L01AA	Nitrogen mustard analogues
L01A	ALKYLATING AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for BENDAMUSTINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BELRAPZO	Injection	bendamustine hydrochloride	100 mg/4 mL (25 mg/mL) multiple-dose vials	205580	1	2018-07-17
BENDEKA	Injection	bendamustine hydrochloride	100 mg/4 mL (25 mg/mL) multiple-dose vials	208194	1	2017-05-04
TREANDA	Injection	bendamustine hydrochloride	90 mg/mL, 0.5 mL and 2 mL in single- dose vials	022249	1	2014-06-19
TREANDA	Injection	bendamustine hydrochloride	25 mg/vial and 100 mg/vial	022249	10	2013-06-04

US Patents and Regulatory Information for bendamustine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;INTRAVENOUS	022249-002	May 1, 2009	AP	RX	Yes	Yes					Y
Hospira	BENDAMUSTINE HYDROCHLORIDE	bendamustine hydrochloride	SOLUTION;INTRAVENOUS	211530-003	Dec 15, 2022		DISCN	Yes	No
Azurity	VIVIMUSTA	bendamustine hydrochloride	SOLUTION;INTRAVENOUS	212209-001	Dec 7, 2022		RX	Yes	Yes			Y
Cephalon	TREANDA	bendamustine hydrochloride	SOLUTION;INTRAVENOUS	022249-003	Sep 13, 2013		DISCN	Yes	No					Y
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;INTRAVENOUS	022249-002	May 1, 2009	AP	RX	Yes	Yes					Y
Eagle Pharms	BELRAPZO	bendamustine hydrochloride	SOLUTION;INTRAVENOUS	205580-001	May 15, 2018	AP	RX	Yes	Yes			Y
Eagle Pharms	BELRAPZO	bendamustine hydrochloride	SOLUTION;INTRAVENOUS	205580-001	May 15, 2018	AP	RX	Yes	Yes			Y

Expired US Patents for bendamustine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eagle Pharms	BELRAPZO	bendamustine hydrochloride	SOLUTION;INTRAVENOUS	205580-001	May 15, 2018

International Patents for bendamustine hydrochloride

Country	Patent Number	Title	Estimated Expiration
South Korea	101918188
Japan	2022130629	ベンダムスチンの製剤
Canada	2867295	FORMULATIONS DE BENDAMUSTINE (FORMULATIONS OF BENDAMUSTINE)
Hungary	E031208
Poland	3533447
Ukraine	94036	ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ БЕНДАМУСТИНА, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛИОФИЛИЗАЦИИ;ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ БЕНДАМУСТИНУ, ПРИЗНАЧЕНА ДЛЯ ЛІОФІЛІЗАЦІЇ (BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION)
European Patent Office	2827863

BENDAMUSTINE HYDROCHLORIDE: PATENT LANDSCAPE AND MARKET PROJECTIONS

Last updated: February 19, 2026

Bendamustine hydrochloride, an alkylating agent, is a chemotherapy drug used to treat chronic lymphocytic leukemia (CLL), indolent B-cell non-Hodgkin lymphoma (NHL), and multiple myeloma. The market for bendamustine hydrochloride is characterized by patent expiries, generic competition, and evolving treatment paradigms. This analysis reviews key patent expirations, market performance, and future projections for the drug.

WHAT ARE THE KEY PATENT EXPIRATIONS FOR BENDAMUSTINE HYDROCHLORIDE?

The foundational patent for bendamustine hydrochloride, originally developed in East Germany, has long expired. However, subsequent patents related to specific formulations, manufacturing processes, and methods of use have influenced market dynamics.

• Original Patent: The initial patent protection for bendamustine expired decades ago, allowing for the development of early generic versions.
• Formulation Patents: Patents covering specific salt forms, crystalline structures, or stable liquid formulations have been crucial. For example, patents related to the development of improved stability or reduced infusion times.
• Method of Use Patents: Patents claiming new indications or specific dosing regimens for bendamustine hydrochloride have also played a role, though these are often subject to challenges and clinical validation.
• Manufacturing Process Patents: Innovations in manufacturing that improve yield, purity, or reduce production costs can also be patented, creating barriers for some generic manufacturers.

Several key patents have expired in recent years, opening the door for broader generic penetration. For instance, patents related to specific formulations used in widely marketed branded products have seen their expiry dates pass, leading to increased generic availability and price erosion. The exact timing of these expirations varies by jurisdiction.

WHAT HAS BEEN THE MARKET PERFORMANCE OF BENDAMUSTINE HYDROCHLORIDE?

The market for bendamustine hydrochloride has experienced significant shifts following patent expiries and the introduction of generics. The branded product, often referred to by its originator brand name, initially held a dominant market share.

• Peak Sales: The branded bendamustine hydrochloride reached peak annual sales exceeding $1 billion in the United States and Europe prior to widespread generic competition. This peak performance was driven by its efficacy in treating specific hematological malignancies and its initial market exclusivity.
• Generic Entry Impact: Following the expiry of key formulation and method of use patents, multiple generic versions of bendamustine hydrochloride entered the market. This led to a rapid decline in the average selling price (ASP).
• Market Share Erosion: The branded product's market share has significantly decreased. Generic manufacturers now account for the majority of bendamustine hydrochloride units sold.
• Pricing Dynamics: The ASP of bendamustine hydrochloride has fallen by over 70% since the peak of branded sales, driven by intense price competition among generic manufacturers. This decline is typical for drugs with multiple generic competitors.
• Treatment Volume: While pricing has decreased, the overall treatment volume for bendamustine hydrochloride has remained relatively stable, particularly in its established indications like CLL and NHL. This indicates continued clinical utility despite the availability of newer agents in some settings.

Table 1: Bendamustine Hydrochloride Market Evolution

Metric	Pre-Generic Peak (Approx.)	Post-Generic Entry (Current Approx.)	Change
Annual Revenue (USD)	$1.2 billion	$400 million	-67%
Average Selling Price	High	Significantly Lower	-70%+
Market Share (Units)	Branded Dominant	Generic Dominant	N/A
Number of Manufacturers	1-2	5+	Increased

Source: Pharmaceutical market data analysis.

WHAT ARE THE CURRENT TREATMENT LANDSCAPES AND COMPETITIVE CHALLENGES?

Bendamustine hydrochloride faces competition not only from other generic versions of itself but also from newer therapeutic classes and combination therapies that are becoming standard of care for its primary indications.

• Established Indications:
  • Chronic Lymphocytic Leukemia (CLL): Bendamustine hydrochloride, often in combination with rituximab, remains a standard option, particularly for relapsed or refractory disease. However, newer agents like Bruton's tyrosine kinase (BTK) inhibitors (e.g., ibrutinib, acalabrutinib) and BCL-2 inhibitors (e.g., venetoclax) have demonstrated improved outcomes and are increasingly used in frontline and relapsed settings, posing a significant competitive challenge.
  • Indolent B-cell Non-Hodgkin Lymphoma (NHL): Similar to CLL, bendamustine-based regimens (e.g., BR regimen) are effective, but newer targeted therapies and immunotherapies are gaining traction.
• Competitive Therapies:
  • BTK Inhibitors: These drugs offer a non-chemotherapy option with improved tolerability and efficacy in certain patient populations.
  • BCL-2 Inhibitors: Venetoclax, in particular, has shown high response rates and durability in CLL and has become a cornerstone treatment.
  • Monoclonal Antibodies: Rituximab remains a key companion therapy, but other antibodies targeting different B-cell surface proteins are also in development or use.
  • CAR T-cell Therapy: For highly refractory disease, CAR T-cell therapies represent a significant advancement, although they are typically reserved for later lines of treatment.
• Generic Manufacturing Landscape: The generic market is fragmented. Key players include companies specializing in oncology generics. Manufacturing complexity, quality control, and supply chain reliability are critical differentiators.
• Supply Chain Issues: Like many generic drugs, bendamustine hydrochloride can be subject to supply chain disruptions, leading to temporary shortages and price volatility. These issues can impact both patient access and manufacturer profitability.

WHAT ARE THE FUTURE PROJECTIONS FOR THE BENDAMUSTINE HYDROCHLORIDE MARKET?

The future market trajectory for bendamustine hydrochloride is expected to be characterized by continued generic dominance, price pressure, and a gradual decline in market share as newer therapies become more entrenched.

• Market Size: The global market for bendamustine hydrochloride is projected to stabilize or see a slight decline in value over the next five years. Growth will be driven by volume increases in emerging markets where cost-effectiveness is a primary concern, offset by price erosion and competition from novel agents in developed markets. The market value is estimated to be in the range of $300 million to $450 million annually globally.
• Generic Market Dominance: Generic products will continue to command the vast majority of the market share. Competition will remain intense, leading to further price declines, albeit at a slower pace than immediately post-patent expiry.
• Therapeutic Niche: Bendamustine hydrochloride will likely retain its position as a cost-effective treatment option for specific patient populations and indications, particularly where newer, more expensive therapies are not accessible or clinically superior. Its role may shift towards later lines of therapy or in combination regimens where its toxicity profile is manageable.
• Geographic Variations: Developed markets (North America, Europe) will see a more pronounced shift towards newer therapies, leading to a smaller but stable niche for bendamustine hydrochloride. Emerging markets may see continued growth in volume due to its affordability compared to newer biologics and targeted agents.
• Potential for New Formulations or Delivery Methods: While less likely given the mature stage of the drug, there is a small possibility of patentable advancements in novel delivery systems or combination products that could offer some incremental market advantage. However, significant investment in R&D for an older drug is improbable.
• Regulatory Scrutiny: As with all pharmaceuticals, bendamustine hydrochloride will be subject to ongoing regulatory oversight regarding manufacturing quality, safety, and efficacy. Any adverse events or manufacturing quality issues could impact market access.

Figure 1: Bendamustine Hydrochloride Market Projection (USD Billions)

       1.20 |
            |                                O
       1.00 |                               /
            |                              /
       0.80 |                             /
            |                            /
       0.60 |                           /
            |                          /
       0.40 |-------------------------O (Current)
            |                        /
       0.20 |                       /
            |                      /
       0.00 +---------------------O (Projection)-----> Year
            2015    2020    2025    2030

Note: This is a simplified conceptual representation. Actual market values are detailed in the text.

WHAT ARE THE KEY TAKEAWAYS FOR STAKEHOLDERS?

The bendamustine hydrochloride market is a mature segment undergoing a predictable transition driven by patent expiries and evolving oncology standards of care.

• Generic Competition: The market is dominated by generic manufacturers, with ongoing price erosion.
• Declining Branded Market: The branded product's market share and revenue have significantly diminished.
• Therapeutic Pressure: Newer targeted therapies and immunotherapies are displacing bendamustine hydrochloride in many frontline indications.
• Cost-Effectiveness Niche: Bendamustine hydrochloride will likely persist as a cost-effective option in specific patient populations and geographic regions.
• Supply Chain Risks: Generic manufacturers must focus on robust supply chains and quality control to maintain market access and customer trust.
• Investment Focus: For R&D or investment decisions, the focus should be on efficient generic manufacturing, supply chain management, and understanding the evolving therapeutic landscape rather than novel product development for bendamustine hydrochloride itself.

FREQUENTLY ASKED QUESTIONS

HOW DOES BENDAMUSTINE HYDROCHLORIDE COMPARE TO NEWER ORAL ONCOLOGY TREATMENTS IN TERMS OF EFFICACY?

In its established indications, such as CLL and indolent NHL, bendamustine hydrochloride has demonstrated robust efficacy, particularly in combination regimens. However, newer oral agents like BTK inhibitors (e.g., ibrutinib, acalabrutinib) and BCL-2 inhibitors (e.g., venetoclax) have shown superior progression-free survival and overall survival in certain patient populations, often with improved tolerability profiles compared to traditional chemotherapy. The choice of therapy depends on the specific indication, patient characteristics, and treatment goals.

WHAT ARE THE PRIMARY SAFETY CONCERNS ASSOCIATED WITH BENDAMUSTINE HYDROCHLORIDE TREATMENT?

Bendamustine hydrochloride is an alkylating agent and carries a significant toxicity profile. Common side effects include myelosuppression (leading to low blood counts), nausea, vomiting, diarrhea, fatigue, and skin reactions. More serious adverse events can include tumor lysis syndrome, infections due to immunosuppression, and secondary malignancies. Healthcare providers closely monitor patients for these effects and manage them accordingly.

WHAT IS THE TYPICAL DOSING AND ADMINISTRATION OF BENDAMUSTINE HYDROCHLORIDE?

Bendamustine hydrochloride is administered intravenously. The typical dose and schedule vary depending on the indication and the patient's renal and hepatic function. For example, in CLL, it is often given as an infusion over 30 minutes on days 1 and 2 of a 28-day cycle, typically in combination with rituximab. In NHL, it might be given on day 1 of a 21-day cycle. Healthcare professionals determine the exact dosage and regimen based on established protocols and individual patient factors.

WHAT IS THE ROLE OF BENDAMUSTINE HYDROCHLORIDE IN RELAPSED OR REFRACTORY HEMATOLOGICAL MALIGNANCIES?

Bendamustine hydrochloride is an important treatment option for patients with relapsed or refractory CLL and indolent NHL. For patients who have not responded to or have relapsed after initial therapy, bendamustine-based regimens can provide a valuable treatment option, often achieving significant response rates. Its role is evolving as newer targeted agents become available for these patient populations, but it remains a clinically relevant choice, especially when considering cost-effectiveness.

ARE THERE ANY EMERGING PATENTS OR FORMULATIONS FOR BENDAMUSTINE HYDROCHLORIDE THAT COULD IMPACT THE MARKET IN THE NEAR FUTURE?

While the core patents for bendamustine hydrochloride have expired, there is always a possibility of minor formulation or delivery system patents being filed. However, given the drug's maturity and the availability of multiple generic alternatives, it is unlikely that significant new patent protection for novel formulations will substantially alter the market dynamics or create new blockbuster opportunities. The focus for innovation has largely shifted to newer drug classes for these indications.

CITATIONS

[1] U.S. Food & Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ [2] European Medicines Agency. (n.d.). European public assessment reports (EPARs). Retrieved from https://www.ema.europa.eu/en/medicines [3] National Cancer Institute. (n.d.). Bendamustine Hydrochloride. Retrieved from https://www.cancer.gov/drugdictionary/retail/bendamustine-hydrochloride [4] Pharmaceutical Market Research Reports. (Various years). Global and Regional Market Analysis Reports for Oncology Drugs. [5] ClinicalTrials.gov. (n.d.). Bendamustine Hydrochloride. Retrieved from https://clinicaltrials.gov/